Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

RHEUMATOLOGY IN PERSPECTIVE · RHEUMAVIEW

SJÖGREN’S · Clinical trials

What Sjögren clinical trials really tell us

How to read encouraging findings, negative results and unanswered questions

When you read that a trial “worked,” ask what improved: disease activity assessed by clinicians, symptoms that affect daily life, or both? A treatment may improve organ-related disease activity without clearly relieving fatigue or dryness. This guide connects the main studies to a concrete treatment goal. Research doses are described in the professional chapter, not offered as instructions for self-treatment.

What makes a trial result convincing?

Look for a fair comparison and a question chosen in advance. In a randomized trial, people are assigned by chance to the study treatment or a comparison group. Blinding means that participants, assessors, or both do not know which treatment was assigned; this reduces the influence of expectations. A placebo resembles the study treatment but contains none of its active medicine. Depending on the trial, both groups may continue specified background care. Researchers choose the main outcome and its assessment time in advance. “Baseline” means the measurements taken before study treatment starts.

People can improve in both groups because of background care, natural fluctuation and other factors. The treatment effect is estimated from the difference between groups, not just the change in the treated group. A group average does not predict exactly how much one person will improve. Small exploratory studies help identify promising treatments; larger confirmatory studies test whether those findings hold up.

Back to contents ↑

What are the scores measuring?

ESSDAI is a clinician’s score of disease activity across the body, including organ involvement and a laboratory component. ClinESSDAI leaves out that laboratory component. These scores are not a direct measure of how tired or dry you feel. [R28] [R33] [R34] ESSPRI records the patient’s ratings of dryness, fatigue and pain. Eye tests and saliva measurements answer more specific questions, such as how much fluid is produced. CRESS and the candidate version of STAR combine several types of results into a rule for deciding whether a participant has responded.

Meeting that rule does not mean that every symptom improved. [R28] [R33] [R34] Ask whether the trial’s main outcome resembles the problem you want treatment to change. Improvement in one measure does not guarantee improvement in the others. A lower antibody level alone is not proof that daily life has improved.

Back to contents ↑

Hydroxychloroquine: what did JOQUER show?

JOQUER did not show an advantage for hydroxychloroquine (HCQ) on its main combined dryness, pain and fatigue outcome at 24 weeks. It therefore does not support promising that HCQ will reliably relieve this combination of symptoms for everyone. [R20] That does not answer every question about inflammatory joints, skin manifestations or another associated disease. If you take HCQ, ask what it was prescribed to treat and how that goal is being reviewed before changing treatment because of a study headline.

Back to contents ↑

Rituximab and abatacept: why negative findings matter

TRACTISS did not show the expected broad benefit of rituximab for fatigue or oral dryness. A large abatacept study also failed to show benefit on its main measure of systemic disease activity. Both findings matter, even though there are sound biological reasons to study these drugs. [R21] [R22] These results help prevent treatment based only on theory. They do not settle every question about uncommon, serious organ complications. An isolated improvement in a blood test or saliva measurement does not make the main negative result disappear. Ask whether the proposed use matches the problem and the people actually studied.

Back to contents ↑

Belimumab and treatment sequences

An early belimumab study reported improvement in some participants but had no placebo group. Without that comparison, it is harder to tell how much improvement came from the medicine. A later small randomized study of belimumab followed by rituximab reduced B cells more deeply and showed an encouraging pattern of disease activity. It did not provide definitive proof of benefit in routine care. [R47] [R25] B cells are part of the immune system. Reducing their number more completely is not itself the goal of treatment.

The questions are whether people function better, organs are protected and the benefit outweighs the risk of infections and other harms. A combination also needs its own safety evidence; the safety of each medicine alone is not enough.

Back to contents ↑

RepurpSS and NECESSITY: new uses for established medicines

RepurpSS-I and the 2026 RepurpSS-II study tested leflunomide with HCQ in adults with active systemic disease. Both found a benefit on their disease-activity outcome; the second study included 46 people. [R23] [R24] Repeating a positive result is encouraging. It does not show that the combination helps everyone whose main difficulty is fatigue or dryness with little systemic activity. Familiar medicines still have meaningful risks and require monitoring. Leflunomide needs special consideration around pregnancy and plans to conceive.

“Existing” and “affordable” do not mean suitable for unsupervised use. [R23] [R24] NECESSITY provides a newer, preliminary finding for HCQ combinations. Its ACR 2026 conference abstract reported a STAR response at week 24 in about 54% with hydroxychloroquine (HCQ) plus mycophenolate mofetil and 52% with HCQ plus leflunomide, compared with 24% on placebo. STAR combines several aspects of disease; these percentages do not mean that each symptom improved. [R64] The clearest difference was in the group with substantial symptoms but low systemic activity.

Results were inconclusive in the smaller group with more systemic activity and when another combined measure, CRESS, was used. Serious adverse events were more frequent in the HCQ–mycophenolate group. These conference findings are worth discussing with a rheumatologist, but do not justify starting or changing a combination on your own. [R64]

Back to contents ↑

Ianalumab: a positive main outcome is not every outcome

Phase III results are published. A modest benefit for systemic disease activity has been shown, but a clear benefit for dryness, fatigue and pain has not been established. [R61] Ianalumab targets BAFF-R, a receptor involved in B-cell survival, and reduces B cells. The NEJM report included 275 and 504 randomized participants in NEPTUNUS-1 and NEPTUNUS-2. At week 48, monthly treatment reduced ESSDAI by about 1.3 and 1.0 points more than placebo.

These are differences between group averages, not the improvement that each participant experienced. [R61] The ESSPRI symptom questionnaire and the SSSD symptom diary showed no statistically significant advantage. Neither did the proportion meeting the trial’s response criterion: an ESSDAI reduction of at least 5 points. A positive main result therefore does not establish benefit on every other outcome, including how someone feels day to day. [R61] According to Novartis, as of November 19, 2026, the application to approve ianalumab for Sjögren’s disease is under FDA review. [R67] Earlier Novartis reports describe priority review by the FDA and submissions in the United States, Europe, China and Japan.

Priority review and Breakthrough Therapy designation are regulatory processes, not approval to use the drug for Sjögren’s disease. [R43] [R65] [R66]

Back to contents ↑

Dazodalibep: separate studies for separate needs

The phase II program studied two groups: people with active systemic disease, and people with substantial symptoms but less systemic activity. The main question differed between the groups: improvement in systemic activity or relief of symptoms. [R28] Status: Phase III OASIZ-301 showed a benefit for systemic activity; the separate OASIZ-303 symptom study is still ongoing. Dazodalibep remains investigational. [R62] Dazodalibep interrupts immune-cell communication involving CD40L. Amgen’s OASIZ-301 report of November 11 describes 648 randomized participants.

At week 48, the average ESSDAI reduction was 5.6 points with treatment every four weeks, 5.2 every twelve weeks and 3.8 with placebo. The extra average reductions over placebo were 1.8 and 1.4 points, respectively; both differences were statistically significant under the trial’s prespecified analysis. [R62] The every-four-week regimen also improved patient-reported dryness compared with placebo. This report does not establish a separate benefit for pain or fatigue. Earlier phase II symptom findings remain useful background.

OASIZ-303 is the separate phase III study needed to assess benefit in people selected for a high symptom burden. [R28] [R62]

Back to contents ↑

Telitacicept: promising results with a country-specific milestone

Telitacicept has phase II evidence and a reported positive phase III study conducted in China. The phase III study enrolled 381 participants and compared two doses with placebo alongside standard treatment. [R30] [R31] RemeGen’s June 2026 disclosure reports Chinese approval for adults with active disease who are receiving conventional treatment. Approval applies to a particular country and use; it does not authorize the medicine elsewhere. Full risks, applicability to other groups of patients and results from the international program still need separate assessment. [R32] [R41]

Back to contents ↑

Nipocalimab and efgartigimod: similar target, different evidence

Nipocalimab and efgartigimod both act on FcRn, a pathway that helps keep IgG antibodies in the blood. In DAHLIAS, the higher tested nipocalimab dose improved clinician-assessed systemic activity compared with placebo. The lower dose did not show a statistically significant benefit. [R33] Status: The phase III UNITY study was stopped for futility, meaning it was unlikely to demonstrate the planned benefit. Efgartigimod is not an established treatment for Sjögren’s disease. [R63] The small RHO trial of efgartigimod had an encouraging early result on a combined response measure, but did not formally test a statistical hypothesis.

It could not establish efficacy on its own. On October 8, 2026, argenx announced that an independent committee recommended stopping UNITY because it was unlikely to meet its main goal for clinical disease activity at week 48. The reason was insufficient expected benefit; no new safety signal was reported. [R34] [R63]

Back to contents ↑

Iscalimab, signaling drugs and low-dose IL-2

Iscalimab’s results for systemic disease activity were more convincing than its results for symptoms. Remibrutinib also showed a possible benefit for systemic activity without a clear symptom benefit. A trial of filgotinib, lanraplenib and tirabrutinib did not meet its main goal. A promising way of acting on the immune system is not enough to establish clinical benefit. [R35] [R36] [R37] A small trial of low-dose interleukin-2 (IL-2), an immune signaling protein, reported benefit, but needs broader confirmation. Reassuring safety findings in a small group cannot exclude uncommon harms.

These are research findings, not a list of interchangeable treatments to try independently. [R38]

Back to contents ↑

What can a dryness study prove?

A small diquafosol study in people with Sjögren dry eye measured tear volume after a single drop. It can help answer a short-term question about moisture at the eye surface. It cannot show that glands regrow or that the whole disease is controlled over the long term. [R39] Check whether a dry-eye or dry-mouth trial actually included people with Sjögren. Studies in other causes of dryness may help inform care, but do not answer the same question directly. Better moisture, symptom relief and prevention of tissue damage are related goals that require different measurements.

Back to contents ↑

How should a trial influence my next decision?

Before a trial result changes your treatment, ask: were the participants similar to you, did the outcome measure the problem you want to improve, and how much extra benefit was seen over the comparison treatment? Then consider the uncertainty, possible harms, visits or other treatment burdens, local authorization and access. If you are considering participation, check the current registry and ask the individual study center. “Active” may mean that follow-up continues while recruitment is closed. A registry entry does not prove that a treatment works.

The chapter on new treatments provides dated study cards and questions about visits, randomization, background treatment and follow-up after participation. [R41] [R44]

Back to contents ↑

Sources

  1. [R20] Gottenberg et al. Hydroxychloroquine: JOQUER randomized trial (2014)
  2. [R21] Bowman et al. Rituximab: TRACTISS randomized trial (2017)
  3. [R22] Baer et al. Abatacept phase III randomized trial (2021)
  4. [R23] van der Heijden et al. RepurpSS-I (2020)
  5. [R24] Wong et al. RepurpSS-II (2026)
  6. [R25] Mariette et al. Sequential belimumab and rituximab (2022)
  7. [R26] Bowman et al. Ianalumab phase 2b dose-finding trial (2022)
  8. [R27] Novartis: NEPTUNUS-1/2 phase III results presented at ACR (29 October 2025)
  9. [R28] St Clair et al. Dazodalibep phase II: two populations (2024)
  10. [R29] Amgen: OASIZ 301 positive topline announcement (22 September 2026)
  11. [R30] Xu et al. Telitacicept phase II (2023 online; 2024 issue)
  12. [R31] Vor Bio/RemeGen: China telitacicept phase III ACR data (14 October 2025)
  13. [R32] RemeGen statutory disclosure: telitacicept Sjögren indication approval (9 June 2026)
  14. [R33] DAHLIAS: nipocalimab phase II (Lancet 2025)
  15. [R34] Peene et al. Efgartigimod RHO proof-of-concept trial (2026)
  16. [R35] Fisher et al. Iscalimab TWINSS phase 2b (2024)
  17. [R36] Dörner et al. Remibrutinib LOUiSSE phase II (2024)
  18. [R37] Price et al. Filgotinib, lanraplenib and tirabrutinib phase II (2022)
  19. [R38] He et al. Low-dose interleukin-2 randomized trial (2022)
  20. [R39] Yokoi et al. Diquafosol tear-volume pilot in Sjögren dry eye (2016)
  21. [R41] ClinicalTrials.gov: named late-stage Sjögren programs
    Additional source recordshttps://clinicaltrials.gov/study/NCT05349214https://clinicaltrials.gov/study/NCT06104124https://clinicaltrials.gov/study/NCT06245408https://clinicaltrials.gov/study/NCT05673993https://clinicaltrials.gov/study/NCT07404865https://clinicaltrials.gov/study/NCT04968912https://clinicaltrials.gov/study/NCT06741969https://clinicaltrials.gov/study/NCT05817669https://clinicaltrials.gov/study/NCT07760818https://clinicaltrials.gov/study/NCT03905525https://clinicaltrials.gov/study/NCT04035668https://clinicaltrials.gov/study/NCT03100942https://clinicaltrials.gov/study/NCT02446249
  22. [R43] Novartis: FDA Breakthrough Therapy designation for ianalumab (16 January 2026)
  23. [R44] Sjögren Foundation: find a clinical trial
  24. [R46] Novartis Q3 2025 results: NEPTUNUS numerical table, slide 17
  25. [R47] Mariette et al. BELISS open-label phase II study (2015)
  26. [R61] NEPTUNUS-1/2: randomized phase III trials, NEJM (21 October 2026)
  27. [R62] Amgen: OASIZ-301 numerical phase III results (11 November 2026)
  28. [R63] argenx: phase III UNITY stopped for futility (8 October 2026)
  29. [R64] Mariette et al. NECESSITY: ACR 2026 abstract LB15
  30. [R65] Novartis Q1 2026: ianalumab priority review and regulatory submissions (28 April 2026)
  31. [R66] Novartis: NEPTUNUS extension and pending regulatory review (10 November 2026)
  32. [R67] Novartis: Meet Novartis Management, November 19, 2026; slide 25 (ianalumab for Sjögren’s disease under FDA review)

Personal educational publication by Olga Goodman, MD. This is not a clinic portal or an emergency service. Any private expert service is separate from clinic accounts and insurance billing. Reuse requires attribution and a link to the original publication.

dr.rheumaview.com · Olga Goodman, MD

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Clinical evidenceClinical trialsSjögren disease